Pasar al contenido principal

Marta Martínez Vicente

I am senior researcher at the VHIR, I’m a Principal Investigator at the Neurodegenerative Diseases Group and I head the Autophagy and Lysosomal Dysfunction lab.

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Neurodegenerativas
Vall Hebron Institut de Recerca
Marta Martínez Vicente

Marta Martínez Vicente

Marta Martínez Vicente

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Neurodegenerativas
Vall Hebron Institut de Recerca

I am senior researcher at the VHIR, I’m a Principal Investigator at the Neurodegenerative Diseases Group and I head the Autophagy and Lysosomal Dysfunction lab.

I obtained a degree in Chemistry/Biochemistry and a PhD in Biochemistry by the University of Valencia. From 2004 to 2008, I worked as a postdoctoral researcher at the laboratory of Dr. Ana Maria Cuervo at the Albert Einstein College of Medicine (New York, USA), focusing on the role of autophagy in neurodegenerative diseases and aging.
I obtained in 2010 a tenure-track position as Miguel Servet I in the Neurodegenerative Diseases Group of the VHIR and since January 2016 I became VHIR Senior Researcher (Miguel Servet II-A).
Currently, the efforts of my team are devoted to study the role of autophagy in neurodegeneration. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease and has been shown to be one of the main causes that contribute to neuronal death in these pathologies. Our efforts are currently directed to: 1) Study the role of the autophagic and lysosomal dysfunction in Parkinson’s disease; 2) Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity; 4) Unravel the link between Parkinson and lysosomal storage diseases, 4) Characterize the defective lysosomal-mediated turnover of mitochondria and aggregates in Huntington’s disease and its contribution to neurodegeneration.
I’ve been able to turn my group into a reference group in the study of autophagy in neurodegeneration and aging. This position is endorsed by our publications, projects, dissemination activities and participation in scientific organizations. Bibliographic parameters: h-index: 31. Citations: >12.000, Publications: 49 scientific articles and mean impact factor/publication in the last 6 years = 10.6. I’ve been PI of several research projects funded by public agencies like ISCIII and MINECO as well as private entities as the Michael J. Fox Foundation, the Silverstein foundation and the BBVA Foundation, in addition I have also been PI in several collaboration agreements with private biotech companies.
I’m member of the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), member and part of the management committee (board member) of the Spanish Autophagy Network (SEAFAGIA), member and part of the management committee of the European COST TRANSAUTOPHGAY network, member and part of the Scientific Advice Committee of the Women in Autophagy (WIA), member of the Spanish Society of Biochemistry and Molecular Biology (SEBBEM), and member of the Association of Women Researcher and Technologists (AMIT). As member of theses scientific societies I participated in the organization of national and international scientific conferences and I am member of the Editorial Board of Cells (ISSN 2073-440). I am in possession of the accreditation of Associate Professor/Researcher by the Agència per a Qualitat del Sistema Universitari de Catalunya (AQU).

Líneas de investigación

Pathogenic role of autophagic/lysosomal dysfunction in Parkinson's disease

Autophagy is the degradation of intracellular components inside the lysosomes and it is essential for the maintenance of cellular homeostasis and neuronal viability. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease and has been shown to be one of the main causes that contribute to neuronal death in these pathologies.


Our efforts are currently directed to:

- Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity.

- Development of new autophagy pharmacological modulators (mTOR-independent) as a therapeutic strategy in neurodegenerative diseases.

IP: Martínez Vicente, Marta, Vila Bover, Miquel

Mitophagy impairment in Huntington's disease

Defective lysosomal-mediated turnover of mitochondria may play a pathogenic role in Huntington’s disease neurodegeneration.

IP: Martínez Vicente, Marta

Role of autophagy in neurodegeneration

The main focus of our research is to study the role of autophagy in neurodegeneration.

Autophagy is the degradation of intracellular components inside the lysosomes and it is essential for the maintenance of cellular homeostasis and neuronal viability. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease,  and has been shown to be one of the main causes that contribute to neuronal death in these pathologies.

 

Our efforts are currently directed to:

- Study the pathogenic role of autophagic/lysosomal dysfunction in Parkinson's disease

- Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity through nanoencapsulation.

- Development of new autophagy pharmacological modulators (mTOR-independent) as a therapeutic strategy in neurodegenerative diseases.

- Study  selective autophagy in Huntington’s disease: charaterization of mitophagy impairment in Huntington’s disease.

IP: Martínez Vicente, Marta

Proyectos

Malalties neurodegeneratives

IP: Vila Bover, Miquel
Colaboradores: Hernández Vara, Jorge, Compte Barrón, Joan, Martínez Vicente, Marta, Bove Badell, Jordi, Malalties neurodegeneratives , Camprodon Gomez, Maria, Malalties neurodegeneratives , Guillard Sirieix, Camille, Lorente Picón, Marina, Laura Castillo Ribelles, de Fabregues-Boixar Nebot, Oriol, Hoyo Pérez, Javier, Laguna Tuset, Ariadna, Cuadros Arasa, Thais, Riera Heredia, Jordi, Ramos Vicente, David, Malalties neurodegeneratives , Malalties neurodegeneratives , Xicoy Cortada, Helena, Nicolau Vera, Alba, González Sepúlveda, Marta, Malalties neurodegeneratives , Cladera Sastre, Joana Margalida, Parent , Annabelle, Daniela Samaniego Toro, Malalties neurodegeneratives
Entidad financiadora: AGAUR no fer servir-correcte 4301-37
Financiación: 40000
Referencia: 2021 SGR 00784
Duración: 01/01/2022 - 31/12/2024

New nanotechnological therapy for Parkinson ?s disease: nose to brain delivery of GBA-polymer nanoconjugates

IP: Martínez Vicente, Marta
Colaboradores: Castillo Sánchez, Pablo, Perez Lasarte, Laia
Entidad financiadora: AGAUR no fer servir-correcte 4301-37
Financiación: 73383.97
Referencia: AGAUR/FI/2023/CASTILLO
Duración: 01/06/2023 - 31/05/2026

New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN)

IP: Martínez Vicente, Marta
Colaboradores: Arranz Amo, José Antonio, New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN), Laura Castillo Ribelles, Clara Carnicer Cáceres, Moreno Martinez, David, Riera Heredia, Jordi, New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN), Castillo Sánchez, Pablo
Entidad financiadora: Fundació "La Caixa"
Financiación: 249950
Referencia: HR22-00602
Duración: 01/11/2022 - 31/10/2025

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Martínez Vicente, Marta
Colaboradores: Arranz Amo, José Antonio, Hernández Vara, Jorge, Guillem Pintos Morell, Clara Carnicer Cáceres, Lorenzo Bosquet, Carles, Moreno Martinez, David, Riera Heredia, Jordi, Daniela Samaniego Toro, Laura Castillo Ribelles
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 245932.5
Referencia: PI20/00728
Duración: 01/01/2021 - 30/06/2025

Noticias relacionadas

La Semana de la Ciencia se dirige a todos los públicos y tiene como objetivos hacer accesible la ciencia y la tecnología a la ciudadanía y fomentar las vocaciones científicas entre los más jóvenes.

El Dr. Miquel Vila, jefe del grupo de investigación en Enfermedades Neurodegenerativas del VHIR, es el copresidente del comité organizador local. Y la Dra. Ariadna Laguna, investigadora principal del mismo grupo, es embajadora científica.

Los Premios Best in Class reconocen los mejores servicios y unidades del Estado, tanto públicos como privados, que buscan la excelencia en la atención que prestan a sus pacientes.

Profesionales relacionados

Daniel Campos Fernández

Daniel Campos Fernández

Investigador predoctoral
Grupo de Investigación del Estado Epiléptico y Epilepsia Aguda
Leer más
Sergio Espinosa Gil

Sergio Espinosa Gil

Investigador predoctoral
Proteínas kinasas y cáncer
Leer más
Herminio Garcia Miguelez

Herminio Garcia Miguelez

Shock, Disfunción Orgánica y Resucitación
Leer más
Christian Eduardo Romero Mesones

Christian Eduardo Romero Mesones

Investigador predoctoral
Neumología
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.